⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MRK News
Merck & Co., Inc.
Myasthenia Gravis Clinical Trial Pipeline Expands as 25+ Companies Race to Redefine Myasthenia Gravis Treatment Landscape | DelveInsight
globenewswire.com
IMVT
ROIV
MRK
NVS
REGN
UCB
JNJ
ARGX
AMGN
VIR
IPHA
ARWR
APLS
CABA
Global Sustainability Awards 2026 Opens Final Call for Entries as Industry Leaders Prepare to Celebrate Sustainability Excellence
globenewswire.com
GOOGL
MRK
RCL
SMR
DigiCert Research Reveals Major Certificate Visibility Blind Spot for Enterprises
globenewswire.com
MSFT
GOOG
AMZN
IBM
ORCL
CSCO
DELL
HPQ
INTC
QCOM
NVDA
AMD
AVGO
MU
AMAT
LRCX
KLAC
ADI
TXN
NXPI
MRVL
SNPS
CDNS
ADSK
CRM
ACN
INFY
SAP
PANW
CRWD
OKTA
FTNT
DDOG
NOW
MCHP
ON
LULU
BBY
COST
HD
LOW
TJX
MDT
AMGN
GILD
BMY
PFE
MRK
JNJ
ABBV
LLY
BIIB
REGN
VRTX
AZN
SNOW
SMCI
PLTR
AI
GOOGL
IAVI to Advance Vaccine Candidate for Bundibugyo Virus, Receives Funding from CEPI
accessnewswire.com
MRK
2026 Meijer LPGA Classic for Simply Give Brings Back Fan-Favorite Family Experiences
prnewswire.com
MRK
Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting
accessnewswire.com
MRNA
MRK
D3 Bio Presents First-Line Data for Elisrasib (D3S-001) at ASCO 2026; Next-Generation KRAS G12C Inhibitor Shows Landmark Efficacy in Untreated NSCLC USA - English APAC - English APAC - Traditional Chinese
prnewswire.com
MRK
Phanes Therapeutics Announces Updated Phase 2 Clinical Trial Results of Spevatamig (PT886) in Combination with Chemotherapy in Frontline Treatment of Metastatic PDAC at the 2026 ASCO Annual Meeting
prnewswire.com
MRK
Form 8-K
sec.gov
MRK
Global Battery Materials Appoints Former Samsung Executive Dr. Yi Hyon Paik as Technical Advisor
prnewswire.com
DOW
MRK